Thrombolytic agents

  • H. Ostermann
  • U. Schmitz-Huebner
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 92)


Thrombolytic agents have been in clinical use for about 30 years (Tillet et al. 1955). The classical thrombolytic drugs have been streptokinase and urokinase. Streptokinase has been used in several clinical conditions such as myocardial infarction, pulmonary embolism, deep venous thrombosis and peripheral arterial thrombosis. Its widespread use in the therapy of thrombotic events has been hampered by severe side effects, mainly bleeding and allergic complications. A significant improvement was the discovery and clinical application of urokinase (Hansen et al. 1961) which as a human protein lacked some of the drawbacks of streptokinase. Clot specificity however was still not thought of until the gain in knowledge concerning the fibrinolytic system led to the characterization, purification and clinical application of tissue plasminogen activator (t-PA) (Ranby 1982) and single-chain urokinase plasminogen activator (scu-PA) (Husain et al. 1983). But although these natural substances achieve much attention in clinical studies, interest in the classical substance streptokinase has been renewed recently by coupling it to plasminogen whose biological properties had been modified to improve the thrombolytic capabilities of the complex.


Acute Myocardial Infarction Plasminogen Activator Thrombolytic Therapy Thrombolytic Agent Clot Lysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Acar J, Vahahnian A, Michel P-L, Slama M, Cormier B, Roger V (1987) Thrombolytic treatment in acute myocardial infarction. Sem Thromb Haemost 13:186–200Google Scholar
  2. Alderman EL, Jutzy KR, Berte LE, Miller RG, Friedman JP, Creger WP, Eliastman M (1984) Am J. Cardiol 54:14–19PubMedGoogle Scholar
  3. Amery A, Deloof W, Vermylen J, Verstraete M (1970) Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. Br Med J 4:639–644PubMedGoogle Scholar
  4. Arnesen H, Heilo A, Jocobson E, Ly B, Skaga E (1978) A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 203:457–463PubMedGoogle Scholar
  5. Arnesen H, Hoiset A, Ly B, Godal HC (1982) Streptokinase or heparin in the treatment of deep vein thrombosis—follow up results of a prospective study. Acta Med Scand 211:65–68PubMedGoogle Scholar
  6. Bachmann F, Kruithof EKO (1984) Tissue plasminogen activator: Chemical and physiological aspects. Sem Thromb Haemost 10:6–17Google Scholar
  7. Bando H, Okada K, Matsuo O (1987) Thrombolytic effect of prourokinase in vitro. Fibrinolysis 1:169–176Google Scholar
  8. Been M, de Bono DP, Muir AL, Boulton FE, Hillis WS, Hornung R (1985) Coronary thrombolysis with intravenous anisoylated plasminogen streptokinase complex BRL 26291. Br Heart J 53:253–259PubMedGoogle Scholar
  9. Bode C, Matsueda GR, Hui KY, Haber E (1985) Antibody directed urokinase: a specific fibrinolytic agent. Science 222:1129–1132Google Scholar
  10. Bode C, Runge MS, Newell JB, Matsueda GR, Haber E (1987) Thrombolysis by a fibrin- specific antibody Fab′-urokinase conjugate. J Mol Cell Cardiol 19:335–341PubMedGoogle Scholar
  11. Bode C, Schwarz F, Schuler G, Zimmermann R, Kübler W (1987) Intravenous thrombolytic therapy with single-chain urokinase-type plasminogen activator in patients with myocardial infarction. Thromb Haemost 58:209Google Scholar
  12. Castellino FJ (1984) Biochemistry of human plasminogen. Semin Thromb Haemost 10:18–23Google Scholar
  13. Cella G, Palla A, Sasahara A A (1987) Controversies of different regimens of thrombolytic therapy in acute pulmonary embolism. Sem Thromb Haemost 13:163–169Google Scholar
  14. Cercek B, Lew AS, Laramee P, Shah PK, Peter TC, Ganz W (1987) Time course and characteristics of ventricular arrhythmias after reperfusion in acute myocardial infarction. Am J Cardiol 60:214–218PubMedGoogle Scholar
  15. Chmielewska J, Ranby M, Wiman B (1983) Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31:427–436PubMedGoogle Scholar
  16. Clauss A (1957) Gerinnungsphysiologische Schnellmethode zur Bestimmung des fibrinogens. Acta Haematol 17:237–246PubMedGoogle Scholar
  17. Collen D (1986) Report of the subcommittee on fibrinolysis, Jerusalem, Israel, June 2, 1986. Thromb Haemost 56:415–416Google Scholar
  18. Collen D, Bounameaux H, de Cock F, Lijnen HR, Verstraete M (1986a) Analysis of coagulation and fibrinolysis during intravenous infusion on recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 73:511–517Google Scholar
  19. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinback RC, Brinker JA, Ludbrock PA, Yasuda T, Bulkey BH, Robison AK, Hutter AM, Bell WR, Spadoro JJ, Khaw BA, Grossbard ED (1984) Coronary thrombolysis with recombinant tissue type plasminogen activator: A prospective, randomized, placebo-controlled trial. Circulation 70:1012–1017PubMedGoogle Scholar
  20. Collen D (1985) Report of the meeting of the subcommittee on fibrinolysis, San Diego, Ca, USA, July 13, 1985. Thromb Haemost 54:893Google Scholar
  21. Collen D (1987) Molecular mechanisms of fibrinlysis and their application to fibrin-specific thrombolytic therapy. Journal of Cellular Biochemistry 33:77–86PubMedGoogle Scholar
  22. Collen D (1987) Rebuttal. Synergism of tissue-type plasminogen activator (t-PA) and single- chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:373Google Scholar
  23. Collen D, de Cock F, Demarsin E, Lijnen HR, Stump DC (1986b) Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in vitro. Thromb Haemost 56:35–39Google Scholar
  24. Collen D, Stump DC, van de Werf F (1986c) Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J 112:1083–1084Google Scholar
  25. Collen D, Zamarron C, Lijnen HR, Hoylaerts M (1986d) Activation of plasminogen by pro-urokinase. II. Kinetics. J Biol Chem 261:1259–1266Google Scholar
  26. Colucci M, Paramo JA, Stassen JM, Collen D (1986a) Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. J Clin Invest 78:138–144Google Scholar
  27. Colucci M, Paramo JA, Collen D (1986b) Inhibition of one-chain and of two-chain forms of human tissue type plasminogen activator by the fast acting inhibitor of plasminogen activator in vitro and in vivo. J. Lab Clin Med 108:53–59Google Scholar
  28. Common HH, Seaman AR, Rosch J, Porter JM, Dotter C (1976) A deep vein thrombosis treated with streptokinase or heparin: follow up of a randomized study. Angiology 27:645- 654PubMedGoogle Scholar
  29. Conard J, Samama MM (1987) Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy. Sem Thromb Haemost 13:212–222Google Scholar
  30. Conforti G, Loskutoff DJ (1985) Plasmin and thrombin modulate plasminogen activation by fibro-sarcoma cells. (Abstr.) Thromb Haemost 54:171Google Scholar
  31. Devries SR, Fox KAA, Robison A, Rodriguez RU, Sobel BE (1987) Determinants of clearance of tissue-type plasminogen activator (t-PA) from the circulation. Fibrinolysis 1:17–21Google Scholar
  32. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902PubMedGoogle Scholar
  33. Diefenbach C, Erbel R, Meyer J, Hamm CW, Schofer J, Mathey DG (1987) Dose-finding study of thrombolysis in acute myocardial infarction by single-chain prourokinase. Thromb Haemost 58:208Google Scholar
  34. Duckert F (1984) Thrombolytic therapy. Sem Thromb Haemost 10:87–103Google Scholar
  35. Ehrlich HJ, Bang NU, Little SP, Jaskunas SR, Weigel BJ, Mattier LE, Harms CS Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. Fibrinolysis 1:75–81Google Scholar
  36. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA (1979) A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis, an interim report of prospective trial. Br J Surg 66:806–810Google Scholar
  37. Ferres H, Hibbs M, Standring R (1987) Deacylation studies in vitro on anisoylated plasminogen streptokinase activator complex. Drugs 33(Suppl. 3) (In press)Google Scholar
  38. Fiessinger JN, Aiach M, Capron L, Devanlay M, Vayssairat M, Juillet Y (1981) Effect of local urokinase on arterial occlusions of lower limbs. Thromb Haemost 45:230–232PubMedGoogle Scholar
  39. Fiessinger JN, Aiach M, Lagneau P, Husson JM, Cormier JM, Housset E (1976) Indications de la streptokinase dans les oblitérations arteriélles des membres. Cœur Méd Interne 15:453–459PubMedGoogle Scholar
  40. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I, Collen D (1986) Acute coronary reocclucion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73:347–352PubMedGoogle Scholar
  41. Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH (1984) Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 76:393PubMedGoogle Scholar
  42. Goldhaber SZ, Markis JE, Kessler CM, Meyerovitz MF, Kim D, Vauchan DE, Selwyn AP, Loscalzo J, Dawley DL, Sharma GVRK, Sasahara A, Grossbard EB, Braunwald E (1987) Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator. Sem Thromb Haemost 13:171–176Google Scholar
  43. Graor RA, Risius B, Denny KM, Young JR, Beven EG, Hertzer HR, Ruschhaupt WF, O’Hara PJ, Geisinger MA, Zeich MG (1985) Local thrombolysis in the treatment of thrombosed arteries, bypass grafts and arteriovenous fistulas. J Vase Surg 2:406–414Google Scholar
  44. Graor RA, Risius B, Young JR, Denny K, Beven E.G., Geisinger MA, Hertzer NR, Krajewski LP, Lucas VF, O’Hara PJ, Ruschhaupt WF, Winton S, Zelch MG, Grossbard EB (1986) J Vase Surg 3:115–124Google Scholar
  45. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–401Google Scholar
  46. Gurewich V, Black J, Pannell R (1987) A mechanism for the potentiating effect of urokinase (UK) or tissue plasminogen activator (t-PA) on clot lysis by pro-urokinase (pro-uk). Thromb Haemost 58:439Google Scholar
  47. Gurewich V, Pannell R. (1986) A comparative study of the efficacy and specificity of tissue-plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 44:217–228PubMedGoogle Scholar
  48. Gurewich V, Pannell R (1987) Fibrin binding and zymogenic properties of single-chain urokinase (pro-urokinase). Sem Thromb Haemost 13:146–151Google Scholar
  49. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R (1984) Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J. Clin Invest 73:1731–1739PubMedGoogle Scholar
  50. Gurewich V, Pannell W (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost 57:372PubMedGoogle Scholar
  51. Hamsten A, Wiman B, DeFaire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557–1563PubMedGoogle Scholar
  52. Harrison DG, Ferguson DW, Collins SM, Skorton DK, Ericksen EE, Kioschos JM, Marcus ML, White CW (1984) Re thrombosis after reperfusion with streptokinase: Importance of geometry of residual lesions. Circulation 69:991–999PubMedGoogle Scholar
  53. Hess H, Ingrisch H, Mietaschk A, Rath H (1982) Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med 307:1627–1630PubMedGoogle Scholar
  54. Holmes WE, Pennica D, Blaber, M, Rey MW, Gunzler WA, Steffens GJ, Heynecker HL (1982) Cloning and expression of the gene for pro-urokinase in escherichia coli. Biotechnology 3:923–929Google Scholar
  55. Husain SS, Gurewich V, Lipinski B (1983) Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 220:31–38PubMedGoogle Scholar
  56. Ichinose A, Takio K, Fujikawa K (1986) Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 78:163–169PubMedGoogle Scholar
  57. Johanson L, Nylander G, Hedner U, Nilsson IM (1979) Comparison of streptokinase with heparin: Late results in the treatment of deep vein thrombosis. Acta Med Scand 206:93–98Google Scholar
  58. Kakkar VV, Flanc C, Howe CT, O’Shea M (1969) Treatment of deep vein thrombosis. A trial of heparin streptokinase and arvin. Br Med J 1:806–810PubMedGoogle Scholar
  59. Kakkar VV, Lawrence D (1985) Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. Am J Surg 10:54–63Google Scholar
  60. Kasai S, Arimura H, Nishida M, Suyama T (1985a) Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follow activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 260:2377–2381Google Scholar
  61. Kasai S, Arimura H, Nishida M, Suyama T (1985b) Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells. Cell Struct Funct 10:151–159Google Scholar
  62. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynar C, Fritz JK (1985) The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12 months follow-up report. N. Engl J Med 312:1073–1077PubMedGoogle Scholar
  63. Koren G, Luria MH, Weiss, AT, Kriwisky M, Mosseri M, Lotan C, Applebaum D, Welber S, Sapoznikov D, Ben-David Y, Hasin Y, Gotsman MS (1987) Early treatment of acute myocardial infarction with intravenous streptokinase. A high risk syndrome. Arch Intern Med 147:237–240PubMedGoogle Scholar
  64. Kruithof EKO, Tran-Thang C, Bachmann F (1986b) Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost 55:201–205Google Scholar
  65. Lammer J, Pilger E, Justich E, Neumayer K, Schreyer H. (1985) Fibrinolysis in chronic arteriosclerotic occlusions: Intrathrombotic injections of streptokinase. Radiology 157:45- 50PubMedGoogle Scholar
  66. Lecander I, Astedt B (1986) Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Brit J Haematol 62:221–228Google Scholar
  67. Lijnen HR, van Hoef B, Collen D (1986a) Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 884:402–408Google Scholar
  68. Lijnen HR, Zamarron C, Blabert M, Winkler ME, Collen D (1986b) Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 261:1253–1258Google Scholar
  69. Loscalzo J (1987) The efficacy and relative fibrin-selectivity of prourokinase in patients with acute myocardial infarction. Thromb Haemost 58:209Google Scholar
  70. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parelukar S, Kim JR, Edward N, Zahavi J, Algazyk KM (1977) Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 89:1018–1029PubMedGoogle Scholar
  71. Martin M, Fiebach BJO, Feldkamp M (1983) Ultrahohe Streptokinase-Infusionsbehandlung bei peripheren Gefäßverschlüssen. DMW 108:167Google Scholar
  72. Martin M, Schoop W, Zeitler E (1970) Streptokinase in chronic arterial occlusive disease. JAMA 211:1169–1173PubMedGoogle Scholar
  73. Mathey DG, Schofer J, Sheehan FH, Becher H, Tilsner V, Dodge HT (1985) Intravenous urokinase in acute myocardial infarction. Am J Cardiol 55:878–882PubMedGoogle Scholar
  74. Mauri F (1987) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: short and medium term prognosis. Thromb Haemost 58:224Google Scholar
  75. Monk JP, Heel RC (1987) Anisoylated plasminogen streptokinase activator complex (APSAC). Drugs 34:25–49PubMedGoogle Scholar
  76. Moroi M, Aoki N (1976) Isolation and characterization of alpha-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J. Biol Chem 251:5050Google Scholar
  77. Nakayama Y, Shinohara M, Tani T, Kawaguchi T, Furuta T, Izawa T, Kaise H, Miyazaki W (1986) The plasmin heavy chain-urokinase conjugate: A specific thrombolytic agent. Thromb Haemost 56:364–370Google Scholar
  78. Neuhaus KL, Tebbe U, Sauer G, Kreuze H, Köstering H (1983) High dose intravenous streptokinase in acute myocardial infarction. Clin Cardiol 6:426–434PubMedGoogle Scholar
  79. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Dano K (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 24:6410–6415Google Scholar
  80. Pannell R, Gurewich V (1987) Activation of plasminogen by single-chain urokinase or by two-chain urokinase—A demonstration that single-chain urokinase has a low catalytic activity (prourokinase). Blood 69:22–26PubMedGoogle Scholar
  81. Pathy L (1985) Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 41:657–663Google Scholar
  82. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennet WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 201:214– 221 Google Scholar
  83. Preissner KT, Müller-Berghaus G (1986) Molekulare Wechselwirkungen zwischen Komplement-, Gerinnungs- und Fibrinolysesystem. Hämostaseologie 6:67–81Google Scholar
  84. Rampling MW, Gaffney PJ (1976) The sulfite precipitation method for fibrinogen measurement: its use on small samples in the presence of fibrinogen degradation products. Clin Chim Acta 67:43–52PubMedGoogle Scholar
  85. Ranby M (1982) Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochem Biophys Acta 704:461–469PubMedGoogle Scholar
  86. Rentrop KP, Blanke H, Köstering K, Barsch KR (1979) acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalisation. Clin Cardiol 2:354–363Google Scholar
  87. Rijken DC, Wijngaards G, Zaal de Jong M, Welbergen J (1979) Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 580:140–153PubMedGoogle Scholar
  88. Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J. Biol Chem 257:2920–2925PubMedGoogle Scholar
  89. Roberts WC (1974) Coronary thrombosis and fatal myocardial ischemia. Circulation 49:1–3Google Scholar
  90. Robertson BR, Nilsson IM, Nylander G (1968) Value of streptokinase and heparin in treatment of acute deep vein thrombosis. Acta Chir Scand 134:203–208PubMedGoogle Scholar
  91. Robertson BR, Nilsson IM, Nylander G (1970) Thrombolytic effect of streptokinase as evaluated by phlebography of deep vein thrombosis of the leg. Acta Chir Scand 136: 173–180PubMedGoogle Scholar
  92. Rogers WJ, Mantle JA, Hood JP, Baxley WA, Whitlow PI, Reeves RC, Soto B (1983) Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction. Circulation 68:1051–1061PubMedGoogle Scholar
  93. Samama M, Verdy E, Conard J, Vahanian A, Michel P, van Dreden P, Nguyen G, Horellou MH, Combrisson A, Acar J (1986) Activateur tissulaire du plasminogene (t-PA) dans l’infarctus du myocarde: aspects biologiques. Arch Mal Cœur 11:618–624Google Scholar
  94. Samama MM (1987) Deep vein thrombosis of inferior limbs; Are thrombolytic agents superior to heparin? Sem Thromb Haemost 13:178–180Google Scholar
  95. Satler LF, Green CE, McNamara NM, Lavelle JP, Pallas RS, Pearle DL, Kent KM, Rackley CE (1987) Late angiographic follow-up after successful coronary arterial thrombolysis and angioplasty during acute myocardial infarction. Am J Cardiol 60:210–213PubMedGoogle Scholar
  96. Schröder R, Biamino G, von Leitner ER, Linderer T, Brüggemann T, Heitz J, Voehringer HF, Wegscheider K (1983) Intravenous short term infusion of streptokinase in acute myocardial infarction. Circulation 67:536–548PubMedGoogle Scholar
  97. Seaman AJ, Common HH, Rosch J, Dotter CT, Porter JM, Lindeil TD, Lawler WL, Schlueter WJ (1976) Deep vein thrombosis treated with streptokinase or heparin. A randomized study. Angiology 27:549–553PubMedGoogle Scholar
  98. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, Bär F, Zwaan C, Krauss XH, Remme WJ, Res J, Verheugt FW A, van Domburg R, Lubsen J, Hugfenholtz PG (1986) Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 7:729–742PubMedGoogle Scholar
  99. Sheehan FH, Mathey DG, Schofer J, Dodge HT, Bolson EL (1985) Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction. Circulation 6:1121–1128Google Scholar
  100. Silver MD, Baroldi G, Mariani F (1980) The relationship between acute occlusive coronary thrombi and myocardial infarction studied in 100 consecutive patients. Circulation 61:219- 227PubMedGoogle Scholar
  101. Simoons ML, Serruys PW, van den Brand M, Res J, Verheugt FWA, Krauss XH, Remme WJ, Bär F, de Zwaan C, van der Laarse A, Vermeer F, Lubsen J (1986) Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 7:717–728PubMedGoogle Scholar
  102. Skriver L, Nielsen LS, Stephens R, Dano K (1982) Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem 124:409–414PubMedGoogle Scholar
  103. Soria J, Soria C, Mirshahi M, Xi M, Mirshahi M, Samama MM, Caen JP (1987) Sem Thromb Haemost 13:223–227Google Scholar
  104. Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH (1982) Effect of intravenous streptokinase on acute myocardial infarction. Pooled results from randomized trials. N Engl J Med 307:1180–1182PubMedGoogle Scholar
  105. Taylor FB Jr, Comp PC (1978) Biochemistry of streptokinase. In: Markwardt F (ed.) Fibrinolytics and antifibrinolytics. Berlin: Springer-Verlag, pp 137–149Google Scholar
  106. Tennant SN, Dixon J, Venable TC, Page HL, Roach A, Kaiser AB, Fredericksen R, Tacogue L, Kaplan P, Babu NS, Anderson EE, Wooten E, Jennings HS, Breinig J, Campbell WB (1984) Intracoronary thrombolysis in patients with acute myocardial infarction: Comparison of the efficacy of urokinase with streptokinase. Circulation 69:756–760PubMedGoogle Scholar
  107. The I.S.A.M. Study Group (1986) A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). N Engl J Med 314:1465–1471Google Scholar
  108. The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 312:932–936Google Scholar
  109. The Urokinase Pulmonary Embolism Trial (1973) A national cooperative study. Circulation 47(Suppl. II): 1–108Google Scholar
  110. Theiss W, Baumann G, Klein G (1987) Fibrinolytische Behandlung tiefer Venenthrombosen mit Streptokinase in ultrahoher Dosierung. DMW 112:668–674Google Scholar
  111. Topol EJ, Bell WR, Weisfeldt ML (1985) Coronary thrombolysis with recombinant tissue-type plasminogen activator. Ann Int Med 103:837–843PubMedGoogle Scholar
  112. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW, and the TAMI Group (1987) A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317:581–588PubMedGoogle Scholar
  113. Topol EJ, O’Neill WW, Langburd AB, Walton JA, Bourdillon PDV, Bates ER, Grines CL, Schork AM, Kline E, Pitt B (1987) A randomized placebo controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty patients with acute myocardial infarction. Circulation 75:420–428PubMedGoogle Scholar
  114. Tsapogas MJ, Peabody RA, Wu KT, Karmdy AM, Devaraj KT, Erkert C (1973) Controlled study of thrombolytic therapy in DVT. Surgery 74:973–984PubMedGoogle Scholar
  115. Urden G, Chmielweska J, Carlsson T, Wiman B (1987) Immunological relationship between plasminogen activator inhibitors from different sources. Thromb Haemost 57:29–34PubMedGoogle Scholar
  116. Urokinase-Streptokinase Pulmonary Embolism Trial. Phase 2 results. (1974) JAMA 229:1606–1613Google Scholar
  117. Van de Loo JCW, Kriessmann A, Trübestein G, Knoch K, de Swart CAM, Asbeck F, Marbet GA, Schmidt HE, Sewell AF, Duckert F, Theiss W, Ritz R (1983) Controlled multicenter pilot study of urokinase-heparin and streptokinase in deep vein thrombosis. Thromb Haemost 50:660–663PubMedGoogle Scholar
  118. Van de Werf F, Nobuhara M, Collen D (1986) Coronary thrombolysis with human single- chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Int Med 104:345–348PubMedGoogle Scholar
  119. Van Mourik JA, Lawrence DA, Loskutoff DJ (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 259:14914- 14921PubMedGoogle Scholar
  120. Van Zonneveld A-J, Veerman H, Brakenhoff JPJ, Aarden LA, Cajot J-F, Pannekoek H (1987) Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins. Thromb Haemost 57:82–86PubMedGoogle Scholar
  121. Verhaghe R, Wilms G, Vermylen J (1987) Local low-dose thrombolysis in arterial disease of the limbs. Sem Thromb Haemost 13:206–211Google Scholar
  122. Verheijen JH, Caspers MPM, Chang GTG, de Munk GAW, Pouwels PH, Enger-Valk BE (1986) Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 5:3525–3530PubMedGoogle Scholar
  123. Verstraete M, Arnold AER, Brower RW, Collen D, de Bono DP, de Zwaan C, Erbel R, Hillis S, Lennane RJ, Lubsen J, Mathey D, Reid DS, Rutsch W, Schartl M, Schofer J, Serruys PW, Simoons ML, Uebis R, Vahanian A, Verheugt FWA, von Essen R (1987) Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol 60:231- 237Google Scholar
  124. Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, de Bono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, Michel PL, Raynaud P, Schofer J, Vahanian A, Vahhaecke J, van de Kley GA, van de Werf F, von Essen R (1985) Double blind randomized trial of intravenous tissue type plasminogen activator versus placebo in acute myocardial infarction. Lancet 11:965–969Google Scholar
  125. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lübsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Scharl M, Schmidt W, Uebis R, von Essen R (1985) Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1:842–847PubMedGoogle Scholar
  126. Walker ID, Davidson JF (1987) Acyl enzymes for thrombolytic therapy. Sem Thromb Haemost 13:139–145Google Scholar
  127. Welzel D, Wolf H (1987) Clinical research on single-chain urokinase-type plasminogen activator (scu-PA) in Germany. Results in patients with acute myocardial infarction. Thromb Haemost 58:47Google Scholar
  128. Williams DO, Borer J, Braunwald E, Chesebro J, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, Markis JE, Mueller H, Desvigne-Nickens P, Passamani ER, Powers ER, Sobel BE, Winniford M, Zaret B (1986) Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial trial. Circulation 73:338–346PubMedGoogle Scholar
  129. Williams JRB (1951) The fibrinolytic activity of urine. Brit J Exp Pathol 32:530–537Google Scholar
  130. Wilms GE, Verhaeghe RH, Pouillon MM, Dewaele D, Baert AJ, Vermylen J, Verstraete M Local thrombolysis in fermoropopliteal occlusions; Early and late results. Cardiovasc Intervent Radiol (In press)Google Scholar
  131. Wun TC, Schleuning WD, Reich E (1982) Isolation and characterization of urokinase from human plasma. J Biol Chem 257:3276–3283PubMedGoogle Scholar
  132. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH (1985) Intravenous and intracoronary fibrinolytic treatment in acute myocardial infarction: Overview of results on mortality, reinfarction, and side effects from 33 randomized controlled trials. Eur Heart J 6:556–585PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • H. Ostermann
    • 1
  • U. Schmitz-Huebner
    • 1
  1. 1.Department of Internal MedicineUniversity of MünsterFederal Republic of Germany

Personalised recommendations